This study aims to evaluate the safety and effectiveness of the tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) + efavirenz (EFV) regimen in antiretroviral therapy (ART)-naive Chinese HIV/AIDS patients.
Inclusion Criteria: * age between 18-65 years of either gender * HIV-1 antibody seropositive detected by ELISA and confirmed by western blot * CD4 cell count \< 500/ul * Signed informed consent, with no condition that precludes follow-up for 2 years * No plan to move out of the area during the trial * antiretroviral therapy naive Exclusion Criteria: * patients in acute phase of HIV infection * patients with ongoing opportunistic infection or AIDS-related malignancies; or with opportunistic infection within previous 3 months and still unstable within 14 days before inclusion * patients with the any of the following test results during screening for inclusion: * WBC count \< 2000/ul, * neutrophil count \< 1000/ul, * Hb \< 9g/dl, * platelet count \< 75000/ul, * serum creatinine \> 1.5 ULN, * transaminases or alkaline phosphatase \> 3 ULN, * total bilirubin \> 2 ULN, * serum creatinine kinase \> 2 ULN * CCr \< 60ml/min * Pregnancy and breastfeeding * Intravenous drug user * Severe neuropathy or mental disorder * history of alcohol abuse and unable to withdrawal * Severe peptic ulcer disease * Non-Chinese nationality